We hypothesized that SGLT2 inhibitor kidney outcome trials are more representative of people with co-existing T2D than those without T2D, and that the EMPA-KIDNEY study is more representative than previous trials. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.